KR101224468B1 - 신규한 형태의 이중표적항체 및 그 용도 - Google Patents

신규한 형태의 이중표적항체 및 그 용도 Download PDF

Info

Publication number
KR101224468B1
KR101224468B1 KR1020090044032A KR20090044032A KR101224468B1 KR 101224468 B1 KR101224468 B1 KR 101224468B1 KR 1020090044032 A KR1020090044032 A KR 1020090044032A KR 20090044032 A KR20090044032 A KR 20090044032A KR 101224468 B1 KR101224468 B1 KR 101224468B1
Authority
KR
South Korea
Prior art keywords
antibody
cancer
target antibody
antibodies
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020090044032A
Other languages
English (en)
Korean (ko)
Other versions
KR20100125033A (ko
Inventor
유진산
이원섭
김성우
심상열
Original Assignee
주식회사 파멥신
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020090044032A priority Critical patent/KR101224468B1/ko
Application filed by 주식회사 파멥신 filed Critical 주식회사 파멥신
Priority to CN200980159382.XA priority patent/CN102428104B/zh
Priority to SG2011082542A priority patent/SG175971A1/en
Priority to DK09844974.7T priority patent/DK2433968T3/en
Priority to ES09844974.7T priority patent/ES2605604T3/es
Priority to JP2012511742A priority patent/JP5744012B2/ja
Priority to RU2011146088/10A priority patent/RU2520824C2/ru
Priority to BRPI0924535-9A priority patent/BRPI0924535B1/pt
Priority to EP09844974.7A priority patent/EP2433968B1/en
Priority to AU2009346447A priority patent/AU2009346447B2/en
Priority to CA2762555A priority patent/CA2762555C/en
Priority to PCT/KR2009/004084 priority patent/WO2010134666A1/ko
Priority to US13/319,899 priority patent/US10125194B2/en
Publication of KR20100125033A publication Critical patent/KR20100125033A/ko
Application granted granted Critical
Publication of KR101224468B1 publication Critical patent/KR101224468B1/ko
Priority to JP2014263739A priority patent/JP2015119705A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
KR1020090044032A 2009-05-20 2009-05-20 신규한 형태의 이중표적항체 및 그 용도 Expired - Fee Related KR101224468B1 (ko)

Priority Applications (14)

Application Number Priority Date Filing Date Title
KR1020090044032A KR101224468B1 (ko) 2009-05-20 2009-05-20 신규한 형태의 이중표적항체 및 그 용도
CA2762555A CA2762555C (en) 2009-05-20 2009-07-22 Dual targeting antibody of novel form, and use thereof
DK09844974.7T DK2433968T3 (en) 2009-05-20 2009-07-22 Dual targeting antibody of novel form and use thereof
ES09844974.7T ES2605604T3 (es) 2009-05-20 2009-07-22 Anticuerpo de dirección doble de forma nueva y uso del mismo
JP2012511742A JP5744012B2 (ja) 2009-05-20 2009-07-22 新規な形態の二重標的抗体およびその使用
RU2011146088/10A RU2520824C2 (ru) 2009-05-20 2009-07-22 Антитело двойной направленности в новой форме и его применение
BRPI0924535-9A BRPI0924535B1 (pt) 2009-05-20 2009-07-22 Anticorpo direcionado a dois alvos e seu método de produção, dna, vetor de expressão recombinante e composição farmacêutica
EP09844974.7A EP2433968B1 (en) 2009-05-20 2009-07-22 Dual targeting antibody of novel form, and use thereof
CN200980159382.XA CN102428104B (zh) 2009-05-20 2009-07-22 双重靶定抗体及其用途
SG2011082542A SG175971A1 (en) 2009-05-20 2009-07-22 Dual targeting antibody of novel form, and use thereof
PCT/KR2009/004084 WO2010134666A1 (ko) 2009-05-20 2009-07-22 신규한 형태의 이중표적항체 및 그 용도
US13/319,899 US10125194B2 (en) 2009-05-20 2009-07-22 Dual targeting antibody of novel form, and use thereof
AU2009346447A AU2009346447B2 (en) 2009-05-20 2009-07-22 Dual targeting antibody of novel form, and use thereof
JP2014263739A JP2015119705A (ja) 2009-05-20 2014-12-26 新規な形態の二重標的抗体およびその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020090044032A KR101224468B1 (ko) 2009-05-20 2009-05-20 신규한 형태의 이중표적항체 및 그 용도

Publications (2)

Publication Number Publication Date
KR20100125033A KR20100125033A (ko) 2010-11-30
KR101224468B1 true KR101224468B1 (ko) 2013-01-23

Family

ID=43126324

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020090044032A Expired - Fee Related KR101224468B1 (ko) 2009-05-20 2009-05-20 신규한 형태의 이중표적항체 및 그 용도

Country Status (13)

Country Link
US (1) US10125194B2 (https=)
EP (1) EP2433968B1 (https=)
JP (2) JP5744012B2 (https=)
KR (1) KR101224468B1 (https=)
CN (1) CN102428104B (https=)
AU (1) AU2009346447B2 (https=)
BR (1) BRPI0924535B1 (https=)
CA (1) CA2762555C (https=)
DK (1) DK2433968T3 (https=)
ES (1) ES2605604T3 (https=)
RU (1) RU2520824C2 (https=)
SG (1) SG175971A1 (https=)
WO (1) WO2010134666A1 (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
KR20120130658A (ko) * 2011-05-23 2012-12-03 주식회사 파멥신 펩타이드가 융합된 이중표적항체 및 그 용도
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
MX354902B (es) 2011-11-23 2018-03-23 Bioven 3 Ltd Proteínas recombinantes y sus usos terapéuticos.
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
DK2924052T3 (da) * 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
KR102049991B1 (ko) 2013-03-28 2019-12-02 삼성전자주식회사 항 c-Met/항 Her2 이중 특이 항체
KR102074421B1 (ko) 2013-03-29 2020-02-10 삼성전자주식회사 항 c-Met/항 EGFR 이중 특이 항체
KR102060540B1 (ko) 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
EP3301115B1 (en) * 2013-05-06 2021-11-10 Sanofi Continuous multistep process for purifying antibodies
KR20150063728A (ko) * 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-C/항 Ang2 이중 특이 항체
KR102223502B1 (ko) 2014-05-09 2021-03-05 삼성전자주식회사 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
AR100271A1 (es) 2014-05-19 2016-09-21 Lilly Co Eli Compuestos de vegfr2 / ang2
CN113975386A (zh) 2014-05-23 2022-01-28 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
KR20160024639A (ko) 2014-08-26 2016-03-07 삼성전자주식회사 c-Met 표적 치료제의 저항성 또는 효능 예측을 위한 바이오마커 PDGF
WO2016060297A1 (ko) * 2014-10-16 2016-04-21 주식회사 파멥신 VEGFR-2 및 c-Met에 대하여 결합성을 갖는 이중표적항체
KR102309881B1 (ko) 2014-11-21 2021-10-06 삼성전자주식회사 c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
US10544220B2 (en) 2015-01-08 2020-01-28 Genmab A/S Bispecific antibodies against CD3 and CD20
IL256562B2 (en) 2015-07-15 2024-07-01 Genmab As Human CD3 antibodies or chimeras
WO2018011421A1 (en) 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
KR102201992B1 (ko) * 2016-09-08 2021-01-12 주식회사 우리기술 clec14a에 특이적으로 결합하는 탈당화 항체 및 그 용도
DK3592769T3 (da) 2017-03-09 2024-08-12 Genmab As Antistoffer mod pd-l1
JP7330942B2 (ja) 2017-03-31 2023-08-22 ジェンマブ ホールディング ビー．ブイ． 二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
CN112055718A (zh) * 2018-03-19 2020-12-08 药物抗体公司 抗vegfr-2抗体
EP3768313A4 (en) * 2018-03-20 2022-01-05 Yuh, Chiou Hwa DUAL-FUNCTIONAL ANTIBODIES AGAINST VEGFR2 AND VEGFR3 DISHES
WO2019183334A1 (en) 2018-03-21 2019-09-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
EP3546475A1 (en) 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
AU2019344300A1 (en) 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin
EP3860715A1 (en) 2018-10-04 2021-08-11 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
CA3118789A1 (en) 2018-11-06 2020-05-14 Genmab A/S Antibody formulation
NL2022494B1 (en) 2019-02-01 2020-08-19 Lava Therapeutics B V Novel CD40-binding antibodies
CN113993893A (zh) 2019-02-01 2022-01-28 拉法医疗有限公司 新cd40结合抗体
JP7447144B2 (ja) * 2019-08-14 2024-03-11 ファームアブシン・インコーポレイテッド 抗ｔｉｅ２抗体及びその用途
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
WO2021155916A1 (en) 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
MX2022009936A (es) 2020-03-18 2022-09-12 Genmab As Anticuerpos que se unen al dominio v-set que contiene el inhibidor de activacion de celulas t 1 (b7h4).
MX2022013797A (es) 2020-05-08 2022-11-30 Genmab As Anticuerpos biespecificos contra cd3 y cd20.
KR20230042035A (ko) 2020-07-08 2023-03-27 라바 테라퓨틱스 엔.브이. Psma와 감마-델타 t 세포 수용체에 결합할 수 있는 항체
KR20230065256A (ko) 2020-08-06 2023-05-11 비온테크 에스이 코로나바이러스 s 단백질용 결합제
US20240034812A1 (en) 2020-09-10 2024-02-01 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
KR20230066040A (ko) 2020-09-10 2023-05-12 젠맵 에이/에스 만성 림프구성 백혈병을 치료하기 위한 cd3 및 cd20에 대한 이중특이적 항체
US20220267450A1 (en) 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
CA3200826A1 (en) 2020-12-10 2022-06-16 Paul Willem Henri Ida PARREN Antibodies that bind gamma-delta t cell receptors
BR112023017099A2 (pt) 2021-02-26 2023-11-21 Lava Therapeutics N V Anticorpos que se ligam a cd123 e a receptores de células t gama-delta
WO2022234146A1 (en) 2021-05-07 2022-11-10 Genmab A/S PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES BINDING TO B7H4 and CD3
BR112023027006A2 (pt) 2021-06-21 2024-03-12 BioNTech SE Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação
EP4384219A4 (en) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
CA3229822A1 (en) 2021-09-13 2023-03-16 Patrick John DOONAN Cd33 x v?2 multispecific antibodies for the treatment of cancer
EP4413039A1 (en) 2021-10-08 2024-08-14 Genmab A/S Antibodies binding to cd30 and cd3
JP2024538958A (ja) 2021-10-21 2024-10-28 ラヴァ・セラピューティクス・エヌ・ヴイ ガンマデルタｔ細胞活性化抗体の使用
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
EP4285926A1 (en) 2022-05-30 2023-12-06 LAVA Therapeutics N.V. Combination treatment for chronic lymphocytic leukemia
EP4292609A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
NL2032398B1 (en) 2022-07-06 2024-01-23 Academisch Ziekenhuis Leiden Bispecific antibody and uses thereof
EP4438624A1 (en) 2023-03-27 2024-10-02 LAVA Therapeutics N.V. Antibodies that bind nectin-4 and gamma-delta t cell receptors
EP4688851A1 (en) 2023-03-27 2026-02-11 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
AR132290A1 (es) 2023-04-05 2025-06-11 Genmab As Composiciones farmacéuticas que comprenden anticuerpos que se unen a cd30 y cd3
TW202509077A (zh) 2023-06-30 2025-03-01 丹麥商珍美寶股份有限公司 與纖維母細胞活化蛋白α及死亡受體４結合之抗體
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
WO2025024780A1 (en) 2023-07-27 2025-01-30 LAVA Therapeutics N.V. Antibodies that bind gamma-delta t cell receptors for the treatment of cancer
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2026078231A1 (en) 2024-10-11 2026-04-16 T-Therapeutics Limited Soluble non-aggregating immune ligand

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
WO1993023550A2 (en) 1992-05-18 1993-11-25 Genentech, Inc. Activation of oligomerizing receptors by using fused receptor ligands
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
EP2298346A3 (en) 2002-03-04 2011-11-16 Imclone LLC Human antibodies specific to kdr and uses thereof
US7531522B2 (en) * 2002-04-22 2009-05-12 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi
CA2516518A1 (en) 2003-02-28 2004-09-10 Lonza Biologics Plc. Antibody purification by protein a and ion exchange chromatography
US20090111146A1 (en) 2003-09-02 2009-04-30 National Institute Of Advanced Industrial Science Antibody Drug
CN100503640C (zh) * 2004-07-08 2009-06-24 中国人民解放军军事医学科学院生物工程研究所 一种抗肿瘤融合蛋白及其编码基因与应用
WO2006005361A1 (en) 2004-07-13 2006-01-19 Centre National De La Recherche Scientifique Peptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
CN1884300A (zh) * 2005-06-24 2006-12-27 中国人民解放军军事医学科学院微生物流行病研究所 一种具有靶向功能的抗肝癌超抗原,其制备方法及用途
WO2008090958A1 (ja) 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. ドメイン交換された遺伝子組換え抗体組成物
KR100883430B1 (ko) * 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
KR102060540B1 (ko) * 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Curr Opin Struct Biol. 2003 Aug,13(4):519-25. *

Also Published As

Publication number Publication date
EP2433968A1 (en) 2012-03-28
KR20100125033A (ko) 2010-11-30
JP5744012B2 (ja) 2015-07-01
EP2433968B1 (en) 2016-09-07
WO2010134666A1 (ko) 2010-11-25
ES2605604T3 (es) 2017-03-15
CA2762555C (en) 2018-02-20
DK2433968T3 (en) 2016-12-19
US20120065380A1 (en) 2012-03-15
JP2012527234A (ja) 2012-11-08
CA2762555A1 (en) 2010-11-25
BRPI0924535B1 (pt) 2021-07-20
AU2009346447B2 (en) 2013-11-14
SG175971A1 (en) 2011-12-29
BRPI0924535A2 (pt) 2015-06-30
EP2433968A4 (en) 2012-12-05
AU2009346447A1 (en) 2011-12-01
US10125194B2 (en) 2018-11-13
RU2011146088A (ru) 2013-06-27
JP2015119705A (ja) 2015-07-02
CN102428104B (zh) 2015-03-04
RU2520824C2 (ru) 2014-06-27
CN102428104A (zh) 2012-04-25

Similar Documents

Publication Publication Date Title
KR101224468B1 (ko) 신규한 형태의 이중표적항체 및 그 용도
RU2597973C2 (ru) Биспецифические двухвалентные антитела анти-vegf/анти-ang-2
JP7778148B2 (ja) 四価ＦＺＤ及びＷＮＴコレセプター（ｃｏ－ｒｅｃｅｐｔｏｒ）結合抗体分子並びにその使用
KR20120130658A (ko) 펩타이드가 융합된 이중표적항체 및 그 용도
KR20230132544A (ko) 신규한 항-그렘린1 항체
KR102444797B1 (ko) α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도
EP3194438A1 (en) Antibodies binding to bmp4, and uses thereof
RU2652880C2 (ru) Антитело против рецептора эпидермального фактора роста
JP2023550673A (ja) ヘルパーＴ細胞ＴＧＦ－βシグナルを特異的に中和する二重特異性抗体、その薬物組成物およびその使用
HK1115302B (en) Antibodies against vascular endothelial growth factor receptor-1
HK1115302A1 (en) Antibodies against vascular endothelial growth factor receptor-1
HK1178177A (en) Bispecific, bivalent anti-vegf/anti-ang-2 antibodies

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U11-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20170109

Year of fee payment: 5

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20180108

Year of fee payment: 6

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

St.27 status event code: A-5-5-R10-R13-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20190110

Year of fee payment: 7

PR1001 Payment of annual fee

Fee payment year number: 7

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 8

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

Fee payment year number: 9

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 10

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 11

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

Not in force date: 20240116

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240116

St.27 status event code: N-4-6-H10-H13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000